source
- FDA approves trastuzumab deruxtecan for early-stage HER2-positive breast cancerThe U.S. Food and Drug Administration has granted approval for trastuzumab deruxtecan (T‑DXd) as a treatment option in both the adjuvant and neoadjuvant settings for certain patients with early-sta…
- Sun Pharma’s $12 billion Organon deal signals global push but India still faces R&D hurdlesSun Pharma is close to completing a nearly $12 billion purchase of Organon, which would lift the Indian group into the world’s top‑25 pharmaceutical companies and expand its footprint to about 150…